Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
NCT05315700
This study is recruiting at 17 US sites in 12 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- ORIC Pharmaceuticals
- Last updated on ClinicalTrials.gov
- September 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 5
- City of Hope · Duarte, CA
- City of Hope · Huntington Beach, CA
- City of Hope · Irvine, CA
- City of Hope · Long Beach, CA
- University of California, San Francisco · San Francisco, CA
Connecticut · 1
- Yale Cancer Center · New Haven, CT
District of Columbia · 1
- Georgetown University · Washington D.C., DC
Florida · 2
- Mayo Clinic · Jacksonville, FL
- Moffitt Cancer Center · Tampa, FL
Illinois · 1
- Northwestern University · Chicago, IL
Massachusetts · 1
- Dana Farber Cancer Institute · Boston, MA
Minnesota · 1
- Mayo Clinic · Rochester, MN
New York · 1
- NYU Langone Health Perlmutter Cancer Center · New York, NY
North Carolina · 1
- Duke Cancer Institute · Durham, NC
Pennsylvania · 1
- University of Pennsylvania · Philadelphia, PA
South Carolina · 1
- Spartanburg Regional Healthcare System · Spartanburg, SC
Virginia · 1
- Next Oncology · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.